**Model Name**
Syngeneic, Lung, KLN 205

**Item Number**
578680

**Introduction**
The KLN 205 murine lung carcinoma model is used to evaluate therapeutic efficacy of investigational antineoplastic agent(s) in immune competent mice of the same background.

**Procedure Summary**
Groups of eight (8), specific-pathogen-free (SPF) female DBA/2 mice bred in an animal isolator (IVC racks) under SPF conditions at 22 ± 2°C are used. Viable murine lung carcinoma KLN 205 (ATCC CRL-1453) cells are injected subcutaneously into the right flank of experimental mice. Dose administrations are initiated when tumor volumes reach 40-80 mm$^3$ (Day 1). Tumor volumes and body weights are measured and recorded twice weekly over the course of the study period. Study will continue for “n” days. Therapeutic efficacy may be evaluated for Tumor Growth Inhibition (TGI), Tumor Growth Delay (TGD), or both TGI and TGD.

**Suggested Testing**
Tumor Growth Inhibition (%TGI) is determined twice weekly by the formula: %TGI = (1 −[(Tn)/(Cn)]) × 100 where Tn = mean tumor volume of treated group on day “n”, and Cn = mean tumor volume of control group on day “n”. Tumor Growth Delay (%TGD) is expressed as the percentage by which the treated group median tumor volume is delayed in reaching the established tumor volume endpoint compared to the controls using the formula ((T-C)/C)) x 100 where T and C are median times (days) to reach the established tumor volume endpoint for the treated and control group, respectively.

**Endpoint Parameters**
Recommended tumor volume endpoint: 1500 mm$^3$

**Study Parameters**
Tumor volume (mm$^3$) is estimated according to the prolate ellipsoid formula: Length (mm) x [Width (mm)]$^2$ x 0.5.

**Reference Compound(s)**
Paclitaxel, 25 mg/kg, IV, qod x 5; anti-CTLA-4, 20 mg/kg, IP, q4d x 3; anti-PD-L1, 20 mg/kg, q4d x 3; anti-PD-1, 20 mg/kg, IP, q4d x 3

**Supplemental Data**
Baseline immune cell data generated from naïve tumor bearing mice: Lymphoid cell populations (CD4+, CD8+, T-reg) and Myeloid cell populations (Dendritic cells, MDSC, Neutrophils) within the tumor.

**Optional Services**
- In Vitro cell proliferation
- MTD determination
- PK and bio-analysis for plasma and tumor
- Clinical chemistries and CBC data collection
- Continuous infusion dose administration (osmotic pump)
- Tumor and organ sampling
- Ex vivo sample analyses using flow cytometry

For current details about our Company address and contact information, please reference our website [http://www.pharmacologydiscoveryservices.com/company-info/](http://www.pharmacologydiscoveryservices.com/company-info/)
Literature

Related Assay(s) (Item # - Assay Name)
578700 - Syngeneic, Lung, LL/2

Modified Protocols
We will readily accommodate client-specified alterations.

Laboratory
These assays are performed at our AAALAC accredited laboratory in Taipei.

Animal Welfare
All aspects of this work is performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

Therapeutic Response Data

Two-way ANOVA followed by Bonferroni post-tests were applied for comparison between the vehicle and test substance-treated groups (*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001).
Baseline Immune Cell Data

Baseline Immune Cell Data: KLN 205 Tumor

Mean Percentage (%)

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dendritic Cells</td>
<td>2.5 ± 0.5</td>
</tr>
<tr>
<td>MDSCs</td>
<td>4.5 ± 0.2</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>6.5 ± 0.3</td>
</tr>
<tr>
<td>CD4+ T</td>
<td>7.0 ± 0.4</td>
</tr>
<tr>
<td>CD8+ T</td>
<td>1.0 ± 0.1</td>
</tr>
<tr>
<td>T-reg</td>
<td>0.5 ± 0.1</td>
</tr>
</tbody>
</table>

Last modified July 17, 2018